The Pharmacogenomic Consideration of Lipid Homeostasis: Role of Pharmacist in Ethical and Economic Consideration


Usage of lipid lowering drugs is a common therapeutic steps in preventing or treating diseases. With the advent of Pharmacogenetics and Pharmacogenomics, it is now important to understand the implication of pharmacogenetic testing in patient care. Ethical and economic concerns are wide considered to be an issue in a pharmacy setting and it is important that the health care professionals in the pharmacy setting need to be aware. This article encompasses current pharmacogenomic information that is relevant to lipid homeostasis and addressed the concerns of patient that may be a factor in ultimate decision making process.

Share and Cite:

P. Serafin and M. Newaz, "The Pharmacogenomic Consideration of Lipid Homeostasis: Role of Pharmacist in Ethical and Economic Consideration," Pharmacology & Pharmacy, Vol. 4 No. 1, 2013, pp. 115-120. doi: 10.4236/pp.2013.41017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. J. Chasman, D. Posada, L. Subrahmanyan, N. R. Cook, V. P. Stanton Jr. and P. M. Ridker, “Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction,” JAMA, Vol. 291, No. 23, 2004, pp. 2821-2827.
[2] C. L. Snozek, et al., “LDLR Promoter Variant and Exon 14 Mutation on the Same Chromosome Are Associated with an Unusually Severe FH Phenotype and Treatment Resistance,” European Journal of Human Genetics, Vol. 17, No. 1, 2009, pp. 85-89. doi:10.1038/ejhg.2008.199
[3] G. Schmitz and T. Langmann, “Pharmacogenomics of Cholesterol-Lowering Therapy,” Vascular Pharmacology, Vol. 44, 2006, pp. 75-89. doi:10.1016/j.vph.2005.07.012
[4] The SEARCH Collaborative Group, “SLCO1B1 Variants and Statin-Induced Myopa-thy—A Genomewide Study,” The New England Journal of Medicine, Vol. 359, No. 8, 2008, pp. 789-799.
[5] Celera Advertisement, “KIF6-StatinCheck Genotype Test,” Heartlab, Berkeley, 2010.
[6] T. Sakaeda, T. Nakamura and K. Okumura, “MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics,” Biological & Pharmaceutical Bulletin, Vol. 25, No. 11, 2002, pp. 1391-1400.
[7] E. F. Christa, P. E. Mullis and A. V. Pandey, “Reduction in Hepatic Drug Metabolizing CYP3A4 Activities Caused by P450 Oxidoreductase Mutations Identified in Patients with Disordered Steroid Metabolism,” Biochemical and Biophysical Research Communications, Vol. 401, No. 1, 2010, pp. 149-153.
[8] C. Q. Lai, D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, et al., “Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants, The GOLDN Study,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, No. 6, 2007, pp. 1417-1425.
[9] M. J. Garcia-Calvo, J. Lisnock, H. G. Bull, et al., “The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1),” Proceedings of the National Academy of Sciences, Vol. 102, No. 23, 2005, pp. 8132-8137.
[10] W. Nicholas, “Cost of Decoding a Genome Is Lowered,” The New York Times, 11 August 2009.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.